Health Care [ 6/12 ] | Biotechnology [ 19/75 ]
NASDAQ | Common Stock
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism.
The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 25 | -0.18 Increased by +18.18% | -0.22 Increased by +18.18% |
| Sep 17, 25 | -0.26 Increased by +40.91% | -0.21 Decreased by -21.89% |
| May 13, 25 | -0.27 Increased by +20.59% | -0.24 Decreased by -12.50% |
| Feb 11, 25 | -0.22 Increased by +18.52% | -0.26 Increased by +15.38% |
| Nov 11, 24 | -0.22 Increased by +21.43% | -0.33 Increased by +33.33% |
| Sep 19, 24 | -0.44 Decreased by -76.00% | -0.33 Decreased by -33.33% |
| May 15, 24 | -0.34 Decreased by -13.33% | -0.30 Decreased by -13.33% |
| Feb 13, 24 | -0.27 Decreased by -3.85% | -0.30 Increased by +10.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -18.15 M Decreased by -18.03% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 46.00 K Decreased by -20.69% | -24.39 M Decreased by -6.15% | Decreased by -53.02 K% Decreased by -33.85% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -18.91 M Decreased by -10.93% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -15.73 M Decreased by -13.09% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -15.38 M Decreased by -5.88% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 58.00 K Increased by +N/A% | -22.98 M Decreased by -80.52% | Decreased by -39.61 K% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -17.05 M Decreased by -8.79% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -13.91 M Decreased by -2.60% | Decreased by N/A% Decreased by N/A% |